BOSTON – Thermo Fisher Scientific Chemicals, Inc., an affiliate of the Waltham-based Thermo Fisher Scientific, Inc. (Thermo Fisher), has agreed to pay $25,000 to resolve allegations that it violated the Controlled Substances Act, by improperly purchasing and distributing chemicals regulated by the Act. Thermo Fisher self-disclosed these violations to the Drug Enforcement Administration (DEA).
The Controlled Substances Act regulates the manufacturing, purchasing and distribution of certain chemicals that can be used to manufacture scheduled controlled substances. The Act allows only DEA registrants to engage in certain activities relative to listed chemicals and requires DEA registrants to, among other things, inform the DEA of sales of listed chemicals to foreign entities. These provisions are designed to ensure that only appropriate entities handle listed chemicals that can be used to manufacture scheduled controlled substances.
Under the settlement agreement, Thermo Fisher acknowledges that it failed to file export declarations when distributing listed chemicals to foreign customers; distributed listed chemicals to a Thermo Fisher location that did not have appropriate DEA registrations; and purchased listed chemicals from suppliers that did not have appropriate DEA registrations.
United States Attorney Rachael S. Rollins and Brian D. Boyle, Special Agent in Charge of the Drug Enforcement Administration, Boston Field Division, made the announcement today. Assistant U.S. Attorney Evan Panich of Rollins’ Affirmative Civil Enforcement Unit handled the case.